血液ベースバイオマーカーの世界市場：市場規模・シェア・動向分析 (種類別・用途別・技術別・最終用途別・地域別)、セグメント別予測 (2025年～2030年)

血液ベースバイオマーカー市場の成長と動向：

Grand View Research社の最新レポートによると、世界の血液ベースバイオマーカー市場規模は2030年までに115億8,000万米ドルに達する見込みです。

同市場は2025年から2030年にかけてCAGR 7.2％で拡大すると予測されています。慢性疾患の有病率の上昇と研究および資金調達の拡大が、血液ベースバイオマーカー産業を牽引します。非侵襲的な診断ツールの需要が高まるにつれ、政府、民間企業、研究機関は、がん、心血管疾患、神経疾患など幅広い疾患に対する血液ベースバイオマーカーの開発と検証に焦点を当てた研究への資金提供を優先しています。このような投資の拡大は、革新的なブレークスルーを可能にし、バイオマーカーの精度と信頼性を高め、新しい診断検査の商業化を加速します。さらに、学術機関、バイオテクノロジー企業、ヘルスケアプロバイダー間の協力関係の高まりは、新規技術の市場開拓を促進し、市場の拡大と患者の治療成績の向上をさらに促進します。

ハイスループットスクリーニング、次世代シーケンシング（NGS）、質量分析における技術革新がバイオマーカー検出の感度と精度を高めるため、技術の進歩と上市が市場を大きく牽引しています。これらの進歩により、以前は検出できなかったバイオマーカーの同定が可能になり、血液検査で診断できる疾患の範囲が拡大します。さらに、マイクロ流体デバイスやウェアラブルセンサーの開発により、より迅速で費用対効果が高く、侵襲性の低い検査が可能になりました。技術が向上し続けるにつれて、血液ベースバイオマーカーアッセイのスケーラビリティと臨床応用性が向上し、疾患の早期発見、個別化医療、治療効果のモニタリングのために、より利用しやすく価値のあるものとなり、市場の成長を後押ししています。

エグザクト・サイエンシズ社（Exact Sciences Corp.）の血液ベースの大腸がんスクリーニング検査に関する有望な性能データの発表は、血液ベースバイオマーカー分野における大きな進歩、すなわち早期発見検査の有効性の高まりを浮き彫りにしています。CRCに対する感度は88.3％、進行した前がん病変に対する感度は31.2％で、特異度は90.1％と高く、このような検査の成功は、がん検診における血液ベースの診断の可能性が高まっていることを裏付けています。より革新的な血液ベースの検査が高い精度と信頼性を実証するにつれて、こうした非侵襲的な早期発見ソリューションに対する需要が急増し、市場のさらなる進歩が促進されると予想されます。このような進展は投資を促し、患者の転帰を向上させ、複数のがん種における血液ベースバイオマーカーの採用を強化します。

血液ベースバイオマーカー市場：分析概要

• 2024年、遺伝子バイオマーカー分野は血液ベースバイオマーカー産業で最大の収益を生み出す分野でした。これは、包括的なゲノムプロファイリングの進歩により、血液ベースの診断における遺伝子バイオマーカーの採用が拡大しているためです。
• がんは、早期診断のための血液ベースバイオマーカーを開発するための一貫した研究、業界リーダー間の広範な共同研究により、2024年に最も支配的なセグメントでした。がん患者の増加とそれに伴う診断のための非侵襲的方法に対する需要の高まりが、このセグメントの成長を後押ししています。
• 次世代シーケンシング（NGS）分野が2024年に市場を独占したのは、技術の進歩と革新的な血液ベースバイオマーカー開発に注力する主要企業の増加によるものです。
• 病院・診療所セグメントは、2024年に最終用途セグメントで最大のシェアを占めました。この優位性は、慢性疾患の有病率の上昇に起因しています。病院は、血液ベースバイオマーカー検査のようなすべての高度な診断サービスの中心であるため、患者は確立された病院を信頼し、市場の成長を促進します。
• 北米地域は2024年に世界市場のトップに君臨します。先進的な診断ツールの導入の増加、認知度の向上、同地域における業界リーダーの存在、規制当局の承認などが市場成長に寄与すると予想されます。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 血液ベースバイオマーカー市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• 血液ベースバイオマーカー市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 血液ベースバイオマーカー市場：種類別の推定・動向分析

• 世界の血液ベースバイオマーカー市場：ダッシュボード、種類別
• 世界の血液ベースバイオマーカー市場：変動分析、種類別
• 世界の血液ベースバイオマーカー市場：種類別 (収益ベース)
• 遺伝子バイオマーカー
• タンパク質バイオマーカー
• 代謝バイオマーカー
• 細胞ベースバイオマーカー
• エピジェネティックバイオマーカー

第5章 血液ベースバイオマーカー市場：用途別の推定・動向分析

• 世界の血液ベースバイオマーカー市場：ダッシュボード、用途別
• 世界の血液ベースバイオマーカー市場：変動分析、用途別
• 世界の血液ベースバイオマーカー市場：用途別 (収益ベース)
• がん
• 心血管疾患
• 神経疾患
• 免疫疾患
• その他

第6章 血液ベースバイオマーカー市場：最終用途別の推定・動向分析

• 世界の血液ベースバイオマーカー市場：ダッシュボード、最終用途別
• 世界の血液ベースバイオマーカー市場：変動分析、最終用途別
• 世界の血液ベースバイオマーカー市場：最終用途別 (収益ベース)
• 病院・クリニック
• 診断検査室
• 研究・学術機関
• その他

第7章 血液ベースバイオマーカー市場：地域別の推定・動向分析（種類別、用途別、技術別・最終用途別）

• 地域別ダッシュボード
• 血液ベースバイオマーカー市場：変動分析、地域別 (2018～2030年)
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 最近の動向と影響分析：主要市場参入企業別
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店・チャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析 (2024年)
  • Abbott
  • BIOMERIEUX
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc
  • Cleveland Diagnostics, Inc.
  • Sysmex Corporation

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 4 Global Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 5 Global Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 6 Global Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 7 Global Blood Based Biomarkers, by Region, 2018 - 2030 (USD Billion)
• Table 8 North America Blood Based Biomarkers, by Country, 2018 - 2030 (USD Billion)
• Table 9 North America Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 10 North America Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 11 North America Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 12 North America Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 13 U.S. Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 14 U.S. Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 15 U.S. Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 16 U.S. Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 17 Canada Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 18 Canada Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 19 Canada Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 20 Canada Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 21 Mexico Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 22 Mexico Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 23 Mexico Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 24 Mexico Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 25 Europe Blood Based Biomarkers, by Country, 2018 - 2030 (USD Billion)
• Table 26 Europe Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 27 Europe Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 28 Europe Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 29 Europe Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 30 Germany Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 31 Germany Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 32 Germany Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 33 Germany Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 34 UK Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 35 UK Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 36 UK Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 37 UK Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 38 France Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 39 France Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 40 France Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 41 France Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 42 Italy Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 43 Italy Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 44 Italy Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 45 Italy Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 46 Spain Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 47 Spain Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 48 Spain Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 49 Spain Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 50 Denmark Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 51 Denmark Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 52 Denmark Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 53 Denmark Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 54 Sweden Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 55 Sweden Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 56 Sweden Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 57 Sweden Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 58 Norway Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 59 Norway Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 60 Norway Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 61 Norway Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 62 Asia Pacific Blood Based Biomarkers, by Country, 2018 - 2030 (USD Billion)
• Table 63 Asia Pacific Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 64 Asia Pacific Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 65 Asia Pacific Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 66 Asia Pacific Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 67 China Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 68 China Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 69 China Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 70 China Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 71 Japan Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 72 Japan Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 73 Japan Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 74 Japan Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 75 India Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 76 India Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 77 India Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 78 India Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 79 South Korea Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 80 South Korea Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 81 South Korea Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 82 South Korea Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 83 Australia Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 84 Australia Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 85 Australia Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 86 Australia Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 87 Thailand Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 88 Thailand Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 89 Thailand Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 90 Thailand Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 91 Latin America Blood Based Biomarkers, by Country, 2018 - 2030 (USD Billion)
• Table 92 Latin America Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 93 Latin America Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 94 Latin America Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 95 Latin America Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 96 Brazil Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 97 Brazil Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 98 Brazil Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 99 Brazil Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 100 Argentina Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 101 Argentina Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 102 Argentina Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 103 Argentina Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 104 Middle East & Africa Blood Based Biomarkers, by Country, 2018 - 2030 (USD Billion)
• Table 105 Middle East & Africa Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 106 Middle East & Africa Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 107 Middle East & Africa Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 108 Middle East & Africa Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 109 South Africa Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 110 South Africa Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 111 South Africa Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 112 South Africa Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 113 Saudi Arabia Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 114 Saudi Arabia Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 115 Saudi Arabia Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 116 Saudi Arabia Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 117 UAE Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 118 UAE Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 119 UAE Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 120 UAE Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)
• Table 121 Kuwait Blood Based Biomarkers, by Type, 2018 - 2030 (USD Billion)
• Table 122 Kuwait Blood Based Biomarkers, by Application, 2018 - 2030 (USD Billion)
• Table 123 Kuwait Blood Based Biomarkers, by Technology, 2018 - 2030 (USD Billion)
• Table 124 Kuwait Blood Based Biomarkers, by End Use, 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Blood Based Biomarkers Market Segmentation
• Fig. 8 Market Snapshot, 2024
• Fig. 9 Market Trends & Outlook
• Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 14 Porter's Five Forces Analysis
• Fig. 15 Global Blood Based Biomarkers Market: Type Movement Analysis
• Fig. 16 Global Blood Based Biomarkers Market, for Genetic Biomarkers, 2018 - 2030 (USD Billion)
• Fig. 17 Global Blood Based Biomarkers Market, for Protein Biomarkers, 2018 - 2030 (USD Billion)
• Fig. 18 Global Blood Based Biomarkers Market, for Metabolic Biomarkers, 2018 - 2030 (USD Billion)
• Fig. 19 Global Blood Based Biomarkers Market, for Cell-Based Biomarkers, 2018 - 2030 (USD Billion)
• Fig. 20 Global Blood Based Biomarkers Market, for Epigenetic Biomarkers, 2018 - 2030 (USD Billion)
• Fig. 21 Global Blood Based Biomarkers Market, for Application, 2018 - 2030 (USD Billion)
• Fig. 22 Global Blood Based Biomarkers Market, for Cancer, 2018 - 2030 (USD Billion)
• Fig. 23 Global Blood Based Biomarkers Market, for Cardiovascular Diseases, 2018 - 2030 (USD Billion)
• Fig. 24 Global Blood Based Biomarkers Market, for Neurological Diseases, 2018 - 2030 (USD Billion)
• Fig. 25 Global Blood Based Biomarkers Market, for Immunological Diseases, 2018 - 2030 (USD Billion)
• Fig. 26 Global Blood Based Biomarkers Market, for Others, 2018 - 2030 (USD Billion)
• Fig. 27 Global Blood Based Biomarkers Market, for Technology, 2018 - 2030 (USD Billion)
• Fig. 28 Global Blood Based Biomarkers Market, for Next-Generation Sequencing, 2018 - 2030 (USD Billion)
• Fig. 29 Global Blood Based Biomarkers Market, for Polymerase Chain Reaction, 2018 - 2030 (USD Billion)
• Fig. 30 Global Blood Based Biomarkers Market, for Immunoassays, 2018 - 2030 (USD Billion)
• Fig. 31 Global Blood Based Biomarkers Market, for Mass Spectrometry, 2018 - 2030 (USD Billion)
• Fig. 32 Global Blood Based Biomarkers Market, for Others, 2018 - 2030 (USD Billion)
• Fig. 33 Global Blood Based Biomarkers Market: End Use Movement Analysis
• Fig. 34 Global Blood Based Biomarkers Market, for Hospitals & Clinics, 2018 - 2030 (USD Billion)
• Fig. 35 Global Blood Based Biomarkers Market, for Diagnostic Laboratories, 2018 - 2030 (USD Billion)
• Fig. 36 Global Blood Based Biomarkers Market, for Research & Academic Institutes, 2018 - 2030 (USD Billion)
• Fig. 37 Global Blood Based Biomarkers Market, for Others, 2018 - 2030 (USD Billion)
• Fig. 38 Regional Marketplace: Key Takeaways
• Fig. 39 Regional Outlook, 2024 & 2030
• Fig. 40 Global Blood Based Biomarkers Market: Region Movement Analysis
• Fig. 41 North America Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 42 U.S. Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 43 Canada Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 44 Mexico Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 45 Europe Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 46 Germany Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 47 UK Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 48 France Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 49 Italy Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 50 Spain Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 51 Denmark Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 52 Sweden Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 53 Norway Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 54 Asia Pacific Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 55 Japan Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 56 China Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 57 India Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 58 Australia Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 59 South Korea Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 60 Thailand Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 61 Latin America Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 62 Brazil Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 63 Argentina Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 64 Middle East and Africa Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 65 South Africa Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 66 Saudi Arabia Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 67 UAE Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)
• Fig. 68 Kuwait Blood Based Biomarkers Market, 2018 - 2030 (USD Billion)

Blood Based Biomarkers Market Growth & Trends:

The global blood based biomarkers market size is expected to reach USD 11.58 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.2% from 2025 to 2030. Rise in the prevalence of chronic diseases along with expanding research and funding drives the blood based biomarkers industry. As the demand for non-invasive diagnostic tools increases, governments, private sectors, and research institutions are prioritizing the funding of studies focused on developing and validating blood-based biomarkers for a wide range of diseases, including cancer, cardiovascular disorders, and neurological conditions. This increased investment enables innovative breakthroughs, enhances the accuracy and reliability of biomarkers, and accelerates the commercialization of new diagnostic tests. Additionally, the growing collaboration between academic institutions, biotechnology companies, and healthcare providers fosters the development of novel technologies, further driving market expansion and improving patient care outcomes.

Technological advancements and launches significantly drives the market, as innovations in high-throughput screening, next-generation sequencing (NGS), and mass spectrometry enhance the sensitivity and precision of biomarker detection. These advancements enable the identification of previously undetectable biomarkers, expanding the range of diseases that can be diagnosed through blood tests. Additionally, the development of microfluidic devices and wearable sensors allows for faster, more cost-effective, and less invasive testing. As technology continues to improve, it enhances the scalability and clinical applicability of blood-based biomarker assays, making them more accessible and valuable for early disease detection, personalized medicine, and monitoring treatment efficacy, thus fueling market growth.

The announcement of Exact Sciences Corp.'s promising performance data for its blood-based colorectal cancer screening test highlights a major advancement for the blood-based biomarker sector: the increasing effectiveness of early detection tests. With sensitivity rates of 88.3% for CRC and 31.2% for advanced precancerous lesions, coupled with a high specificity of 90.1%, the success of such tests reinforces the growing potential of blood-based diagnostics in cancer screening. As more innovative blood-based tests demonstrate high accuracy and reliability, the demand for these non-invasive, early detection solutions is expected to surge, driving further advancements in the market. This progress encourages investment, enhances patient outcomes, and strengthens the adoption of blood-based biomarkers across multiple cancer types.

Blood Based Biomarkers Market Report Highlights:

• In 2024, the genetic biomarkers segment was the largest revenue-generating sector of the blood based biomarkers industry. This is attributed to the growing adoption of genetic biomarkers in blood-based diagnostics is driven by advancements in comprehensive genomic profiling.
• Cancer was the most dominating segment in 2024 due to the consistent research, extensive collaborations among industry leaders to develop blood-based biomarkers for early diagnosis. Increasing cases of cancer and thereby rise in the demand for non invasive methods for diagnosis fuel the segment's growth.
• Next-Generation Sequencing (NGS) segment dominated the market in 2024 due to the advancements in the technology and rising focus of several key players to develop innovative blood-based biomarkers.
• Hospitals and Clinics segment held the largest share of the end use segment in 2024. This dominance is attributed to the rising prevalence of chronic diseases. As hospitals are center to all the advanced diagnostic services, such as blood-based biomarker testing, patients entrust the established hospitals thus, fueling market growth.
• The North American region is set to reign the global market in the year 2024. The rising implementation of advanced diagnostic tools, increasing wareness, presence of industry leaders in the region and regulatory approvals are anticipated to contribute to the market growth

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. Technology
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type, application, technology, and end-use outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Blood Based Biomarkers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of chronic diseases
    • 3.2.1.2. Advancements in biomarker technology
    • 3.2.1.3. Expanding research and funding support
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High development and validation costs
    • 3.2.2.2. Lack of reimbursement policies for biomarker treatment
• 3.3. Blood Based Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Social landscape
    • 3.3.2.5. Environmental landscape

Chapter 4. Blood Based Biomarkers Market: Type Estimates & Trend Analysis

• 4.1. Global Blood Based Biomarkers Market: Type Dashboard
• 4.2. Global Blood Based Biomarkers Market: Type Movement Analysis
• 4.3. Global Blood Based Biomarkers Market by Type, Revenue
• 4.4. Genetic Biomarkers
  • 4.4.1. Genetic Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.5. Protein Biomarkers
  • 4.5.1. Protein Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.6. Metabolic Biomarkers
  • 4.6.1. Metabolic Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.7. Cell-Based Biomarkers
  • 4.7.1. Cell-Based Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.8. Epigenetic Biomarkers
  • 4.8.1. Epigenetic Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Blood Based Biomarkers Market: Application Estimates & Trend Analysis

• 5.1. Global Blood Based Biomarkers Market: Application Dashboard
• 5.2. Global Blood Based Biomarkers Market: Application Movement Analysis
• 5.3. Global Blood Based Biomarkers Market by Application , Revenue
• 5.4. Cancer
  • 5.4.1. Cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.5. Cardiovascular Diseases
  • 5.5.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.6. Neurological Diseases
  • 5.6.1. Neurological diseases market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.7. Immunological Diseases
  • 5.7.1. Immunological diseases market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.8. Others
  • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Blood Based Biomarkers Market: End Use Estimates & Trend Analysis

• 6.1. Global Blood Based Biomarkers Market: End Use Dashboard
• 6.2. Global Blood Based Biomarkers Market: End Use Movement Analysis
• 6.3. Global Blood Based Biomarkers Market by End Use, Revenue
• 6.4. Hospitals & Clinics
  • 6.4.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.5. Diagnostic Laboratories
  • 6.5.1. Diagnostic laboratories market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Research & Academic Institutes
  • 6.6.1. 6.6. Research & academic institutes market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.7. Others
  • 6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Blood Based Biomarkers Market: Regional Estimates & Trend Analysis by Type, Application, Technology, and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Abbott
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. BIOMERIEUX
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. F. Hoffmann-La Roche Ltd.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Siemens Healthineers AG
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Thermo Fisher Scientific, Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Bio-Rad Laboratories, Inc
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Cleveland Diagnostics, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Sysmex Corporation
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives